

Friday September 27, 2013

● Mini Session 5 Clinical mini symposia

17.55 - 19.10 3 satellite sessions (selected presentations)

Room 1. Gynecological cancers

Moderators: **William Jacot & Fabien Reyrol, FR**

17.45 DTCs, CTCs and other prognostic biomarkers for ovarian cancer.

What are the top candidates to predict prognosis? **Sabine Kasimir Bauer, DE**

18.05 Matrix metalloproteinase 1 and circulating tumor cells in early breast cancer,

Michal Mego, SK

18.25 HER2 amplification in primary tumor: A potential marker for presence of circulating

tumor cells in non-metastatic inflammatory breast cancer patients, **Carolyn Hall, USA**

18.45 CTC metastasis biology, **Bernadette Jäger, DE**

Room 2. Gastro-intestinal cancers

Moderators: **François-Clément Bidard, USA & Pascale Mariani, FR**

17.45 Circulating tumor cells and colorectal liver surgery, **Lars Thomas Seeberg, NO**

18.05 VEGFR expression on CTCs in colon cancer patients, **Maria Jose Serrano, SP**

18.25 An investigation of Circulating Tumour Cells in Hepatocellular Carcinoma (HCC),

Karen Morris, UK

18.45 Clinical significance of circulating tumor cells in peripheral blood from patients with

gastric cancer, **Yoshikazu Uenosono, JP**

Room 3. Urological cancers

Moderators: **Thierry Lebret & Christophe Massard, FR**

17.45 Characterization of Invasive CTCs (iCTCs) from Men with Metastatic

Castration-Resistant Prostate Cancer (mCRPC), **Terence Friedlander, USA**

18.05 Enumeration and molecular profiling of circulating tumor cells (CTCs) in urothelial

cancer (UC) before and during systemic treatment, **Emanuela Fina, IT**

18.25 Detection and clinical relevance of circulating tumor cells in patients

with testicular germ cell tumors, **Paulina Nastaly, DE**

18.45 CTC detection in localized prostate cancer: EPISPOT-PSA pilot assay,

Thibaut Murez, FR

20.00 - 00.00 Gala Dinner: Paris Rive Droite - Escalé Borély

Boat trip on the «Boréas» along the Seine

Young Investigator Travel Grant & Best Posters awards

● Session 6 Metastasis biology II

Moderator: **Danny Welch, USA**

08.45 Identification of Heterogeneous Stem Cell Populations in Solid Tumors,

Michael F. Clarke, USA

09.05 Lymph node metastases, **Stanley P.L. Leong, USA**

09.25 Exosomes and metastatic niche, **David Lyden, USA**

● Session 7 CTC and other circulating markers

Moderators: **Pierre-Jean Lamy & Ronald Lebofsky, FR**

09.45 Overview: Circulating nucleic acids in cancer patients, **Dave Hoon, USA**

10.00 Tumor exosomes as circulating biomarkers? **Clotilde Théry, FR**

10.20 Coffee break

10.50 Status on disseminated tumor cells in breast cancer, **Bjørn Naume, NO**

11.10 Circulating tumor DNA and microRNA in blood cancer patients,

Heidi Schwarzenbach, DE

11.30 Targeted deep sequencing of circulating tumour DNA and its application

in noninvasive cancer monitoring, **Tim Forshew, UK**

11.50 Detecting circulating tumor DNA: PAP, digital PCR and next generation

sequencing approaches, **Marc-Henri Stern, FR**

12.10 Circulating miRNA in cancer, **George Calin, USA**

12.30 -13.30 Lunch and Poster Session

13.30 -15.00 **Selected oral presentations**

Moderators: **Pierre-Jean Lamy & Ronald Lebofsky, FR**

13.30 DNA Methylation of Tumor Suppressor and Metastasis Suppressor Genes

in Circulating Tumor Cells and corresponding circulating tumor DNA,

Maria Chimonidou, GR

13.45 The identification of circulating micro-RNAs (miRNA) to monitor tumour

burden in mice bearing small cell lung cancer (SCLC) xenografts

established from patient derived circulating tumour cells (CTCs),

Alastair Greystoke, UK

14.00 Circulating Plasma DNA as marker of therapy response in ovarian cancer,

Eva Obermayr, AT

14.15 ctDNA technology applications during metastasis, **Ronald Lebofsky, FR**

14.30 Best oral presentation awards & concluding remarks

Jean-Yves Pierga, Catherine Alix-Panabières, FR & Klaus Pantel, DE

Sponsors

Major sponsors



Janssen Diagnostics



Silver sponsor



Bronze sponsor



sponsors



● Organization

com&co

Com&Co SARL, Etienne Jarry
12, Bd Fellen - 13016 Marseille, France
Tél. +33 (0) 4 91 09 70 53
ejarry@comnco.com
www.comnco.com

● Organizers

Jean-Yves Pierga

MD, PhD, Institut Curie,
Paris Descartes University, France

Catherine Alix-Panabières

Ph.D, University Medical Centre Montpellier,
UM1, Montpellier, France

Klaus Pantel

MD, Ph.D, University Medical Centre
Hamburg-Eppendorf, Hamburg, Germany

www.ismrc2013.com

Scientific Program

Wednesday September 25, 2013

Dear Colleagues and Friends,

We warmly welcome you to the 9th International Symposium on Minimal Residual Cancer 'ISMRC 2013' in Paris.

The research field of tumor dissemination is rapidly expanding. This PARIS ISMRC meeting is a great opportunity to gather during three days, academic researchers, clinicians, and development engineers from the device and the pharmaceutical industries and to share information about the most recent developments, clinical trials and late breaking news.

We are extremely grateful for participation of experts in so various fields to present their latest advances. Research on Circulating and Disseminating Tumor Cells (CTCs/DTCs) is a challenge in deciphering metastatic process, including epithelio-mesenchymal transition, micro-environment, stemness or dormancy. Technological developments for CTC isolation, capture and characterization have led now to a great diversity of approaches that will be reflected by the number of presentations, posters and boosts at this Symposium. Clinical relevance of CTC in oncology as a prognostic marker, monitoring tools or real-time liquid biopsy to adapt targeted therapy will be largely discussed in various tumor types including lung, breast, prostate or colon cancer. Other circulating markers like cell-free nucleic acids (tumor DNA & microRNA) are one of the other main topics of this symposium, as their comparison or complementarity with CTCs are largely debated.

Finally, we would like to express our appreciation to the corporations and organizations that have generously provided financial support to make this conference possible (i.e., awards for travel, presentation and poster).

We hope that you will enjoy your time attending this 9th ISMRC meeting in Paris and take full advantage of the great opportunities to exchange fruitful information and establish meaningful collaborations with your colleagues.

With our best regards,



Catherine Alix-Panabières



Jean-Yves Pierga



Klaus Pantel





- 08.30 Welcome introduction, **Jean-Yves Pierga & Catherine Alix-Panabières, FR**
- 08.35 **Keynote lecture:** CTC-DTC research: State-of-the-art & Perspectives, **Klaus Pantel, DE**
- **Session 1 Metastasis biology I**
Moderators: **Klaus Pantel, DE & Jean-Paul Thiery, SN**
- 09.05 Dormant tumor cell survival and recurrence, **Lewis Chodosh, USA**
- 09.30 Epithelial-Mesenchymal Transition (EMT), **Jean-Paul Thiery, SN**
- 09.55 Microenvironment and Epithelial Mesenchymal Plasticity (EMP) in Breast Cancer, **Erik W. Thompson, AUS**
- 10.20 Coffee break
- 10.50 Influence of the mitochondrial genome on cancer metastasis measured using mitochondrial-nuclear exchange, **Danny Welch, USA**
- 11.10 Metastatic Breast Cancer Stem Cells, **Christophe Ginestier, FR**
- 11.30 Convergence of microenvironmental, self-renewal and quiescence signals regulate disseminated tumor cell dormancy **Julio Aguirre-Ghiso, USA**
- 11.50 Tumor-Stromal Interactions in Bone Metastasis, **Yibin Kang, USA**
- 12.10 Metastasis and bone environment, **Philippe Clézardin, FR**
- 12.30 Lunch and Poster Session
- **Session 2 Novel CTC assays**
Moderators: **Catherine Alix-Panabières & Jean-Louis Viovy, FR**
- 14.00 Challenges in CTC detection, **Catherine Alix-Panabières, FR**
- 14.25 Microfluidic-magnetic sorting of CTC: the best of two worlds? **Jean-Louis Viovy, FR**
- 14.45 Microfluidic biochips for CTC detection and retrieval, **Chwee Teck Lim, SN**
- 15.05 In vivo isolation of circulating tumor cells by the Cell Collector™ system, **Klaus Lücke, DE**
- 15.25 Coffee break
- 15.55 Are filtration-based methods more efficient for the characterization of CTC heterogeneity? **Françoise Farace, FR**
- 16.15 The DEPArray™ System: automated isolation of pure CTCs to bring molecular characterization into clinical routine, **Nicolo Manaresi, Silicon Biosystems**
- 16.30 Novel CTC assays, **Eugen Ermantraut, Alere**
- 16.45 -17.50 **Selected oral presentations**
Moderators: **Catherine Alix-Panabières, FR & Jean-Louis Viovy, FR**
- 16.45 Detection of viable circulating tumor cells by viral infection, **Julia Pietsch, DE**
- 17.00 Identification of Heterogeneous Populations of Circulating Tumor Cells from Patients Using ApoStream™, an Antibody- Independent Cancer Cell Recovery Device, **Kenna Anderes, USA**
- 17.15 Isolation and molecular profiling of a circulating tumor cell by using a novel single cell picking system, **Yuurin Kondo, JP**
- 17.30 In vivo CTC detection using photoacoustic flow cytometry, **Vladimir P. Zharov, USA**

- 17.50 -18.30 **Metastasis biology discussion**
Moderators: **Jean-Yves Pierga & Sergio Roman-Roman, FR**
- 17.50 Primary tumors elicit dormancy of disseminated breast cancer cells in the bone marrow by downregulating Gas6, **Isabel Ben Batalla, DE**
- 17.55 Identification of heterogeneous populations of circulating tumor cells from patients using ApoStream™, an antibody- Independent cancer cell recovery device, **Andrea Benedikova, cz**
- 18.00 CTCs-enriched blood fractions, primary tumors and lymph nodes metastases gene expression profiles and their clinical significance, **Aleksandra Markiewicz, PL**
- 18.05 Breast cancer brain metastasis: interrogating mechanisms of brain colonization by CTC subset profiling and biomarker discovery, **Dario Marchetti, USA**
- 18.10 The transcription factor grainyhead-like 2 (GRHL2) is a regulator of EMT and cell proliferation in breast cancer, **Sabrina Frey, DE**
- 18.15 Capture, culture and functional characterization of viable circulating tumor cells in a syngenic breast cancer mouse model system, **Anthony Williams, USA**
- 18.20 Identifying genomic signatures in circulating tumour cells from breast cancer, **Nisha Kanwar, CA**
- Free evening

Thursday September 26, 2013

- **Session 3 CTC in clinical studies**
Moderators: **David Azria & Jean-Yves Pierga, FR**
- 08.30 Clinical relevance of CTC, **Jean-Yves Pierga, FR**
- 08.50 Molecular characterization of CTC in breast cancer, **Stefanie S. Jeffrey, USA**
- 09.10 CTC in clinical studies: Gastro-Intestinal cancers, **François-Clément Bidard, USA**
- 09.30 PL33 expression in circulating blood is a good marker for colon cancer recurrence, **Masaki Mori, JP**
- 09.50 Circulating tumor cell biomarkers for unmet needs in prostate cancer drug development . and patient management, **Howard Scher, USA**
- 10.10 Coffee break
- 10.40 Lung Cancer CTCs clinical utility and molecular characterisation, **Caroline Dive, UK**
- 11.00 Towards the study of bone marrow DTC in breast and ovarian cancer, **Nikolai Tupitsyn, RU**

- 11.15 - 12.15 **Selected oral presentations**
Moderators: **David Azria & Jean-Yves Pierga, FR**
- 11.15 Urological cancer (non muscle invasive bladder cancer), **Paola Gazzaniga, IT**
- 11.30 Going beyond enumeration: Characterization of CTCs and cancer associated cells in Head and Neck Squamous Cell Carcinoma patients, **Kris R. Jatana & Jeffrey Chalmers, USA**
- 11.45 Circulating tumor cells in non-metastatic triple negative breast cancer, **Anthony Lucci, USA**
- 12.00 Correlation of circulating tumor cells (CTCs) with myeloid-derived suppressive cells (MDSCs) in the peripheral blood of patients with advanced small cell lung carcinoma (SCLC) predicts clinical, **Ippokratis Messaritakis, GR**
- 12.15 - 12.35 Current challenges for clinical implementation of CTC testing, **Costanza Paoletti, USA**
- 12.35 Lunch and Poster Session
- **Session 4 Molecular characterization of CTC**
Moderators: **Evi Lianidou, GR & Michail Ignatiadis, BE**
- 14.00 Challenges in CTC molecular characterization, **Evi Lianidou, GR**
- 14.25 EMT and CTC, **Massimo Cristofanilli, USA**
- 14.45 CTC molecular characterization:
Are we ready to move forward with clinical testing? **Michail Ignatiadis, BE**
- 15.05 mRNA and microRNA profiling of CTCs from metastatic breast and colorectal cancer patients, **Anieta M. Sieuwerts, NL**
- 15.25 Coffee Break
- 16.00 CTC and DTC in breast cancer - what is and will be the clinical utility? **Wolfgang Janni, DE**
- 16.20 Detection and characterization of circulating tumor cells from patients with colorectal cancer, **Sabine Riethdorf, DE**
- 16.40 -17.40 **Selected oral presentations**
Moderators: **Evi Lianidou, GR & Michail Ignatiadis, BE**
- 16.40 The identification of circulating micro-RNAs (miRNA) to monitor tumour burden in mice bearing small cell lung cancer (SCLC) xenografts established from patient derived circulating tumour cells (CTCs), **Cassandra Hodgkinson, UK**
- 16.55 Exploring the genomic heterogeneity among circulating tumor cells by next generation sequencing, **Simon Joosse, DE**
- 17.10 Single cell genetic analysis helps validating cytopathological identification of CTCs in patients with Clear Cells Renal Carcinoma, **Patricia Paterlini, FR**
- 17.25 Morphology and DNA integrity are defining criteria for diagnostic molecular profiles of single CTCs, **Bernard Polzer, DE**